• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume9, Issue3

Efficiency of Fenofibrate in Facilitating the Reduction of Central Macular Thickness in Diabetic Macular Edema

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 3160-3164

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Diabetic macular edema (DME) has been reported at rates of 10% and occurs more frequently in type 2 diabetes mellitus. The present study was conducted to assess the efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema.
Materials & Methods: 60 patients with type 2 diabetes having treatment naïve, center‑involving DME of both genders were divided into 2 groups.  Group I had DME only in one eye and group II had DME in both eyes. Group I were given oral fenofibrate 160 mg/day for 6 months as a single evening dose. Central macular thickness in both groups was compared.
Results: The mean FBS was 137.6 mg/dl in group I and 158.2 mg/dl in group II, PPBS was 210.4 mg/dl and 238.6 mg/dl, blood urea (mg/dl) was 29.3 in group I and 31.5 in group II and serum creatinine (mg/dl) was 0.92 and 0.99 in group I and in group II respectively. CMT in group I and group II at baseline was 432.6 and 402.1, at 2 months was 360.2 and 358.1, at 4 months was 327.5 and 331.4 and at 6 months was 294.3 and 317.6 in group I and in group II respectively. The difference was non- significant (P>0.05).
Conclusion: Fenofibrate facilitate reduction of central macular thickness in patients with diabetic macular edema
Keywords:
    Central macular thickness Diabetic macular edema Fenofibrate
  • PDF (186 K)
  • XML
(2022). Efficiency of Fenofibrate in Facilitating the Reduction of Central Macular Thickness in Diabetic Macular Edema. European Journal of Molecular & Clinical Medicine, 9(3), 3160-3164.
. "Efficiency of Fenofibrate in Facilitating the Reduction of Central Macular Thickness in Diabetic Macular Edema". European Journal of Molecular & Clinical Medicine, 9, 3, 2022, 3160-3164.
(2022). 'Efficiency of Fenofibrate in Facilitating the Reduction of Central Macular Thickness in Diabetic Macular Edema', European Journal of Molecular & Clinical Medicine, 9(3), pp. 3160-3164.
Efficiency of Fenofibrate in Facilitating the Reduction of Central Macular Thickness in Diabetic Macular Edema. European Journal of Molecular & Clinical Medicine, 2022; 9(3): 3160-3164.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 49
  • PDF Download: 120
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus